vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Company profile
Ticker
VIR
Exchange
Website
CEO
George A. Scangos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Agenovir Corporation • Encentrio Therapeutics, Inc. • Encentrio Therapeutics International GmbH • Humabs BioMed SA • TomegaVax, Inc. • Vir AU Biotechnology Pty Ltd. • Vir Biotechnology International GmbH • Vir Predictive Medicine, Inc. • VirAb, Inc. ...
IRS number
812730369
VIR stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
29 May 24
DEFA14A
Additional proxy soliciting materials
14 May 24
10-Q
2024 Q1
Quarterly report
3 May 24
8-K
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
2 May 24
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
18 Apr 24
S-8
Registration of securities for employees
26 Feb 24
10-K
2023 FY
Annual report
26 Feb 24
Latest ownership filings
4
Ramy Farid
31 May 24
3
Ramy Farid
31 May 24
4
NORBERT W BISCHOFBERGER
31 May 24
3
NORBERT W BISCHOFBERGER
31 May 24
4
Backer Marianne De
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
ANN M. HANLY
2 Apr 24
4
Sung Lee
28 Mar 24
4
ANN M. HANLY
26 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 180.47 mm | 180.47 mm | 180.47 mm | 180.47 mm | 180.47 mm | 180.47 mm |
Cash burn (monthly) | 26.94 mm | 55.18 mm | 26.69 mm | 51.75 mm | 36.46 mm | 63.53 mm |
Cash used (since last report) | 55.68 mm | 114.04 mm | 55.17 mm | 106.95 mm | 75.36 mm | 131.30 mm |
Cash remaining | 124.80 mm | 66.44 mm | 125.31 mm | 73.52 mm | 105.12 mm | 49.17 mm |
Runway (months of cash) | 4.6 | 1.2 | 4.7 | 1.4 | 2.9 | 0.8 |
Institutional ownership, Q1 2024
34.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 74 |
Opened positions | 14 |
Closed positions | 91 |
Increased positions | 20 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 73.04 bn |
Total shares | 47.33 mm |
Total puts | 135.90 k |
Total calls | 112.50 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Softbank Vision Fund | 20.26 mm | $0.00 |
ARCH Venture Fund IX | 12.92 mm | $369.42 mm |
GSK GSK | 6.63 mm | $199.31 mm |
Baillie Gifford & Co | 3.95 mm | $39.98 bn |
BK Bank Of New York Mellon | 806.93 k | $8.17 bn |
PFG Principal Financial Group Inc - Registered Shares | 462.03 k | $4.68 bn |
Empowered Funds | 458.04 k | $4.64 bn |
Nordea Investment Management Ab | 235.66 k | $2.41 bn |
Swiss National Bank | 185.20 k | $1.88 bn |
State of Alaska, Department of Revenue | 152.45 k | $1.54 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 May 24 | Bischofberger Norbert W | Common Stock | Grant | Acquire A | No | No | 0 | 16,000 | 0.00 | 16,000 |
29 May 24 | Bischofberger Norbert W | Stock Option Common Stock | Grant | Acquire A | No | No | 10.1 | 16,000 | 161.60 k | 16,000 |
29 May 24 | Bischofberger Norbert W | Stock Option Common Stock | Grant | Acquire A | No | No | 10.1 | 16,000 | 161.60 k | 16,000 |
29 May 24 | Ramy Farid | Common Stock | Grant | Acquire A | No | No | 0 | 16,000 | 0.00 | 16,000 |
29 May 24 | Ramy Farid | Stock Option Common Stock | Grant | Acquire A | No | No | 10.1 | 16,000 | 161.60 k | 16,000 |
29 May 24 | Ramy Farid | Stock Option Common Stock | Grant | Acquire A | No | No | 10.1 | 16,000 | 161.60 k | 16,000 |
3 Apr 24 | Backer Marianne De | Common Stock | Sell | Dispose S | No | No | 9.4577 | 72,995 | 690.36 k | 678,457 |
News
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
24 May 24
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
24 May 24
Vir Biotechnology's SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024
21 May 24
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
7 May 24
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
7 May 24
Press releases
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
29 May 24
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
29 May 24
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
23 May 24
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
22 May 24
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
21 May 24